Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02121483 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus
A Phase 1 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT02121483 is a Phase 1 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 27 participants.
The verdict
NCT02121483, a Phase 1 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The aim of the study is to generate pharmacokinetic and pharmacodynamic data to identify the safe-effective dose of empagliflozin in children and adolescents aged 10 to less than 18 years with type 2 diabetes mellitus.
Interventions
- DRUG empagliflozin medium dose
- DRUG empagliflozin high dose
- DRUG empagliflozin low dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02121483
The ClinicalTrials.gov registry entry for NCT02121483 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which empagliflozin medium dose is the first listed.
NCT02121483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02121483 about?
NCT02121483 is a clinical study titled "Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus". The aim of the study is to generate pharmacokinetic and pharmacodynamic data to identify the safe-effective dose of empagliflozin in children and adolescents aged 10 to less than 18 years with type 2 diabetes mellitus.
What is the current status of trial NCT02121483?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2014-06. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02121483?
The interventions under investigation include: empagliflozin medium dose (DRUG), empagliflozin high dose (DRUG), empagliflozin low dose (DRUG).
Who is sponsoring clinical trial NCT02121483?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.